Nan Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nan Zhang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Jing Tao
Department of Pathology, Children’s Hospital Affiliated to Zhengzhou University, Henan Children’s HospitalZhengzhou Children’s Hospital, Zhengzhou, China
4 shared publicationsXiao Feng
Department of Pathology, Children’s Hospital Affiliated to Zhengzhou University, Henan Children’s HospitalZhengzhou Children’s Hospital, Zhengzhou, China
4 shared publications- Bin Zhang
Department of Dermatology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, 100045, People's Republic of China
1 shared publication - Haohan Wang
Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
1 shared publication - Jia Wang
Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China
1 shared publication - Jian Tian
School of Economics and Management, University of Science and Technology Beijing, Beijing 100083, China
1 shared publication
Latest Publications
- Open Access
- 16 May 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (10) , 1515
Clinicopathological Characterization of Pediatric Atypical Teratoid/Rhabdoid Tumors and an HE–IHC Dual-Path Deep Learning Model for Auxiliary Diagnosis
Background/Objectives: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare and aggressive pediatric embryonal tumor of the central nervous system with marked histological and immunophenotypic heterogeneity, which can make diagnosis difficult in some cases. This study aimed to summarize the clinicopathological and molecular features of pediatric AT/RT and to evaluate an HE–IHC dual-path deep learning model as an auxiliary diagnostic approach. Methods: Clinical, histopathological, immunophenotypic, ultrastructural, and fluorescence in situ hybridization (FISH) data were retrospectively collected from 18 children with AT/RT treated at Beijing Children’s Hospital between February 2010 and April 2021. A total of 361 pathological images were used to train and test a ResNet50-based dual-path classification model with transfer learning and feature fusion. An additional independent test set of 175 histological and immunohistochemical images from six newly collected patients was used for supplementary validation. Results: The mean age at diagnosis was 2 years and 3 months. All cases showed loss of INI1 expression, positivity for CK and EMA, and a high Ki-67 index. FISH analysis identified SMARCB1 deletion in 7 of 15 tested cases. In the original image-based test set, the dual-path model achieved an accuracy of 90.91%, compared with 81.82% for the model without transfer learning, 86.36% for the single-path immunohistochemistry model, and 50.00% for the single-path histological model. In the additional independent test set, the trained model correctly classified all 175 images. Conclusions: Pediatric AT/RT shows diverse clinicopathological features and complex SMARCB1 alteration patterns. The HE–IHC dual-path model showed encouraging preliminary performance for auxiliary pathological assessment; however, larger multicenter cohorts with molecular subgroup annotation are needed for further validation before routine clinical application.
- 16 May 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (10) , 1515
Open AccessClinicopathological Characterization of Pediatric Atypical Teratoid/Rhabdoid Tumors and an HE–IHC Dual-Path Deep Learning Model for Auxiliary Diagnosis
Background/Objectives: Atypical teratoid/rhabdoid tumor (AT/RT) is a rare and aggressive pediatric embryonal tumor of the central nervous system with marked histological and immunophenotypic heterogeneity, which can make diagnosis difficult in some cases. This study aimed to summarize the clinicopathological and molecular features of pediatric AT/RT and to evaluate an HE–IHC dual-path deep learning model as an auxiliary diagnostic approach. Methods: Clinical, histopathological, immunophenotypic, ultrastructural, and fluorescence in situ hybridization (FISH) data were retrospectively collected from 18 children with AT/RT treated at Beijing Children’s Hospital between February 2010 and April 2021. A total of 361 pathological images were used to train and test a ResNet50-based dual-path classification model with transfer learning and feature fusion. An additional independent test set of 175 histological and immunohistochemical images from six newly collected patients was used for supplementary validation. Results: The mean age at diagnosis was 2 years and 3 months. All cases showed loss of INI1 expression, positivity for CK and EMA, and a high Ki-67 index. FISH analysis identified SMARCB1 deletion in 7 of 15 tested cases. In the original image-based test set, the dual-path model achieved an accuracy of 90.91%, compared with 81.82% for the model without transfer learning, 86.36% for the single-path immunohistochemistry model, and 50.00% for the single-path histological model. In the additional independent test set, the trained model correctly classified all 175 images. Conclusions: Pediatric AT/RT shows diverse clinicopathological features and complex SMARCB1 alteration patterns. The HE–IHC dual-path model showed encouraging preliminary performance for auxiliary pathological assessment; however, larger multicenter cohorts with molecular subgroup annotation are needed for further validation before routine clinical application.
- Open Access
- 21 April 2026
- Published by MDPI AG in Neurology International
- Vol. 18 (4) , 74
Atypical Teratoid/Rhabdoid Tumor of the Lateral Ventricle: A Case Series and Experience with Molecular Subtyping-Guided Immunotherapy
Background: Atypical teratoid/rhabdoid tumors (AT/RT) are rare, highly aggressive pediatric central nervous system (CNS) malignancies. AT/RT of the lateral ventricle is an exceptionally rare subgroup, with only 11 reported cases. SMARCB1 inactivation is the primary molecular feature of AT/RT. Current consensus is to classify AT/RT based on methylation and molecular profiles into the following subgroups: AT/RT-TYR, AT/RT-SHH, AT/RT-MYC, and a potentially distinct SMARCA4-deficient subtype. AT/RT-MYC exhibits high levels of CD8+ tumor-infiltrating lymphocytes, indicating immunogenic potential. Case presentation: We report three pediatric cases presenting with intracranial hypertension and seizures. Diagnosis was confirmed via histopathology and molecular profiling. Interventions included gross total resection, chemotherapy, radiotherapy, and combined immune checkpoint inhibitors (pembrolizumab and ipilimumab). Outcomes varied from rapid progression to 3-year recurrence-free survival. A cohort of 14 pediatric patients with lateral ventricle AT/RT, comprising 3 institutional cases and 11 cases identified from the PubMed database, was evaluated through a narrative synthesis. Conclusions: These advancements highlight the crucial role of molecular subtyping in tailoring personalized treatments, including epigenetic modifiers and immune-based regimens. However, clinical validation is essential to establish standardized protocols. Integrating genomic, epigenetic, and immune microenvironment profiling may enhance risk assessment and treatment precision, ultimately improving survival and quality of life in pediatric patients.
- 21 April 2026
- Published by MDPI AG in Neurology International
- Vol. 18 (4) , 74
Open AccessAtypical Teratoid/Rhabdoid Tumor of the Lateral Ventricle: A Case Series and Experience with Molecular Subtyping-Guided Immunotherapy
Background: Atypical teratoid/rhabdoid tumors (AT/RT) are rare, highly aggressive pediatric central nervous system (CNS) malignancies. AT/RT of the lateral ventricle is an exceptionally rare subgroup, with only 11 reported cases. SMARCB1 inactivation is the primary molecular feature of AT/RT. Current consensus is to classify AT/RT based on methylation and molecular profiles into the following subgroups: AT/RT-TYR, AT/RT-SHH, AT/RT-MYC, and a potentially distinct SMARCA4-deficient subtype. AT/RT-MYC exhibits high levels of CD8+ tumor-infiltrating lymphocytes, indicating immunogenic potential. Case presentation: We report three pediatric cases presenting with intracranial hypertension and seizures. Diagnosis was confirmed via histopathology and molecular profiling. Interventions included gross total resection, chemotherapy, radiotherapy, and combined immune checkpoint inhibitors (pembrolizumab and ipilimumab). Outcomes varied from rapid progression to 3-year recurrence-free survival. A cohort of 14 pediatric patients with lateral ventricle AT/RT, comprising 3 institutional cases and 11 cases identified from the PubMed database, was evaluated through a narrative synthesis. Conclusions: These advancements highlight the crucial role of molecular subtyping in tailoring personalized treatments, including epigenetic modifiers and immune-based regimens. However, clinical validation is essential to establish standardized protocols. Integrating genomic, epigenetic, and immune microenvironment profiling may enhance risk assessment and treatment precision, ultimately improving survival and quality of life in pediatric patients.
- 22 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 135
The causal relationship between immune cells and neuroblastoma: a Mendelian randomization study
Neuroblastoma (NB) is a common pediatric malignant tumor, accounting for approximately 13% of childhood cancer-related deaths. It has a poor prognosis, and its pathogenesis and genetic characteristics remain complex. Although recent studies have suggested a potential association between immune cells and NB, the causal relationship remains unclear. In this study, we utilized genome-wide association studies (GWAS) summary statistics of 731 immune traits (n = 3757) and three NB subtypes: MYCN-amplified NB (n = 5369), 11q-deletion NB (n = 5222), and 1p-deletion NB (n = 5178). We conducted Mendelian randomization (MR) analyses to assess the causal relationship between immune cells (exposure) and these NB subtypes (outcome). After false discovery rate (FDR) correction, neither 11q-deletion NB nor 1p-deletion NB showed significant associations with immunophenotypes. However, and only one immunophenotype was positively correlated with the risk of MYCN-amplified NB: HLA DR on monocyte (OR: 1.754 [95% CI = 1.288 to 2.390], p = 3.6 × 10–4, q value = 0.194). Reverse MR analysis did not support a causal effect of MYCN-amplified NB on HLA DR expression in monocytes. Sensitivity analyses further confirmed the stability and reliability of these findings. Our MR study provides strong evidence for a causal relationship between HLA DR on monocyte and MYCN-amplified NB, suggesting that elevated HLA DR expression may be a risk factor for this aggressive subtype. These findings could inform clinical decision-making regarding prognosis and treatment strategies for MYCN-amplified NB and may also identify potential therapeutic targets.
- 22 November 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 135
The causal relationship between immune cells and neuroblastoma: a Mendelian randomization study
Neuroblastoma (NB) is a common pediatric malignant tumor, accounting for approximately 13% of childhood cancer-related deaths. It has a poor prognosis, and its pathogenesis and genetic characteristics remain complex. Although recent studies have suggested a potential association between immune cells and NB, the causal relationship remains unclear. In this study, we utilized genome-wide association studies (GWAS) summary statistics of 731 immune traits (n = 3757) and three NB subtypes: MYCN-amplified NB (n = 5369), 11q-deletion NB (n = 5222), and 1p-deletion NB (n = 5178). We conducted Mendelian randomization (MR) analyses to assess the causal relationship between immune cells (exposure) and these NB subtypes (outcome). After false discovery rate (FDR) correction, neither 11q-deletion NB nor 1p-deletion NB showed significant associations with immunophenotypes. However, and only one immunophenotype was positively correlated with the risk of MYCN-amplified NB: HLA DR on monocyte (OR: 1.754 [95% CI = 1.288 to 2.390], p = 3.6 × 10–4, q value = 0.194). Reverse MR analysis did not support a causal effect of MYCN-amplified NB on HLA DR expression in monocytes. Sensitivity analyses further confirmed the stability and reliability of these findings. Our MR study provides strong evidence for a causal relationship between HLA DR on monocyte and MYCN-amplified NB, suggesting that elevated HLA DR expression may be a risk factor for this aggressive subtype. These findings could inform clinical decision-making regarding prognosis and treatment strategies for MYCN-amplified NB and may also identify potential therapeutic targets.
- 6 August 2024
- Published by Elsevier in Human Pathology
- Vol. 152, 105637
ALK-positive histiocytosis in 12 Asian children
- 6 August 2024
- Published by Elsevier in Human Pathology
- Vol. 152, 105637
ALK-positive histiocytosis in 12 Asian children
- 15 May 2024
- Published by Springer Nature in Molecular Biotechnology
- Vol. 67 (5) , 2098-2110
Differential Gene Analysis of Langerhans Cell Histiocytosis and the Significance of MMP1-Targeted Drug Repositioning
Langerhans cell histiocytosis (LCH) is a rare condition predominantly affecting young children. Activation of the MAPK pathway has offered key new insights into the pathogenesis of LCH; however, the precise mechanisms underlying its occurrence and development are still far from being completely elucidated. There is still a relapse/reactivation rate in patients with multisystem LCH. Therefore, this study aimed to investigate other potential LCH pathophysiologies and prospective therapeutic targets. The gene expression omnibus (GEO) database was used to retrieve gene expression profiles of LCH (GSE16395). Three distinct types of analyses were performed after identifying the common differentially expressed genes (DEGs) in LCH: hub gene identification, functional annotation, module construction, drug repositioning, and expression analysis via immunohistochemistry (IHC). We identified 417 common DEGs and 50 central hub genes. This functional study highlighted the significance of keratinization, skin development, and inflammation. In addition, we predicted new drug candidates (RS2 drugs targeting matrix metalloprotease1, MMP1) that could be used for LCH treatment. Finally, gene-miRNA and gene-TF networks and immune cell infiltration were analyzed for MMP1-related genes. MMP1 expression levels in LCH tissues were validated by IHC. Our study identified the central communal genes and novel drug candidates. These shared pathways and hub genes offer new perspectives on future mechanisms of action and therapeutic targets.
- 15 May 2024
- Published by Springer Nature in Molecular Biotechnology
- Vol. 67 (5) , 2098-2110
Differential Gene Analysis of Langerhans Cell Histiocytosis and the Significance of MMP1-Targeted Drug Repositioning
Langerhans cell histiocytosis (LCH) is a rare condition predominantly affecting young children. Activation of the MAPK pathway has offered key new insights into the pathogenesis of LCH; however, the precise mechanisms underlying its occurrence and development are still far from being completely elucidated. There is still a relapse/reactivation rate in patients with multisystem LCH. Therefore, this study aimed to investigate other potential LCH pathophysiologies and prospective therapeutic targets. The gene expression omnibus (GEO) database was used to retrieve gene expression profiles of LCH (GSE16395). Three distinct types of analyses were performed after identifying the common differentially expressed genes (DEGs) in LCH: hub gene identification, functional annotation, module construction, drug repositioning, and expression analysis via immunohistochemistry (IHC). We identified 417 common DEGs and 50 central hub genes. This functional study highlighted the significance of keratinization, skin development, and inflammation. In addition, we predicted new drug candidates (RS2 drugs targeting matrix metalloprotease1, MMP1) that could be used for LCH treatment. Finally, gene-miRNA and gene-TF networks and immune cell infiltration were analyzed for MMP1-related genes. MMP1 expression levels in LCH tissues were validated by IHC. Our study identified the central communal genes and novel drug candidates. These shared pathways and hub genes offer new perspectives on future mechanisms of action and therapeutic targets.
- Open Access
- 17 April 2024
- Published by Wiley in Pediatric Investigation
- Vol. 8 (2) , 117-125
Somatic GNA11/GNAQ variants in a cohort of Chinese children with phakomatosis pigmentovascularis
Importance: Postzygotic mutations in the GNAQ/GNA11 genes, which encode the G‐protein nucleotide binding protein alpha subunits, have been identified in patients with phakomatosis pigmentovascularis (PPV). However, little is known about the Chinese population.Objective: To identify pathogenic mutations in pediatric patients with PPV within the Chinese population.Methods: We performed whole‐exome sequencing (WES) using skin lesion tissues from pediatric patients diagnosed with PPV. Additionally, ultradeep‐targeted sequencing was conducted to validate the somatic mutations. A genotype‐phenotype correlation was analyzed by integrating data from previous reports with the findings of the present study.Results: Thirteen patients were enrolled, all diagnosed with the cesioflammea type of PPV, except for one patient with an unclassifiable type. We identified somatic GNA11 c.547C>T (p.R183C) variant in seven patients and GNAQ c.548G>A (p.R183Q) in four patients, with low allelic fractions ranging from 2.1% to 8.6% through ultradeep sequencing. Besides, a GNAQ c.548G>A (p.R183Q) variant was detected through targeted sequencing in one of two patients who did not exhibit detectable variants via WES. The genotype‐phenotype correlation analysis, involving 15 patients with a GNA11 variant and 10 with a GNAQ variant, revealed that facial capillary malformation (87% vs. 50%, P = 0.075) and ocular melanocytosis (80% vs. 40%, P = 0.087) appeared to be more frequent in patients with GNA11 mutation compared to those with GNAQ mutations. All four patients diagnosed with cesiomarmorata type or overlapping cesioflammea and cesiomarmorata type PPV carried the GNA11 variant.Interpretation: Our study demonstrated that the majority of PPV patients in the Chinese population carried a postzygotic variant of GNAQ/GNA11, thus further confirming the pathogenic role of GNAQ/GNA11 mosaicism in the development of PPV cesioflammea type.
- 17 April 2024
- Published by Wiley in Pediatric Investigation
- Vol. 8 (2) , 117-125
Open AccessSomatic GNA11/GNAQ variants in a cohort of Chinese children with phakomatosis pigmentovascularis
Importance: Postzygotic mutations in the GNAQ/GNA11 genes, which encode the G‐protein nucleotide binding protein alpha subunits, have been identified in patients with phakomatosis pigmentovascularis (PPV). However, little is known about the Chinese population.Objective: To identify pathogenic mutations in pediatric patients with PPV within the Chinese population.Methods: We performed whole‐exome sequencing (WES) using skin lesion tissues from pediatric patients diagnosed with PPV. Additionally, ultradeep‐targeted sequencing was conducted to validate the somatic mutations. A genotype‐phenotype correlation was analyzed by integrating data from previous reports with the findings of the present study.Results: Thirteen patients were enrolled, all diagnosed with the cesioflammea type of PPV, except for one patient with an unclassifiable type. We identified somatic GNA11 c.547C>T (p.R183C) variant in seven patients and GNAQ c.548G>A (p.R183Q) in four patients, with low allelic fractions ranging from 2.1% to 8.6% through ultradeep sequencing. Besides, a GNAQ c.548G>A (p.R183Q) variant was detected through targeted sequencing in one of two patients who did not exhibit detectable variants via WES. The genotype‐phenotype correlation analysis, involving 15 patients with a GNA11 variant and 10 with a GNAQ variant, revealed that facial capillary malformation (87% vs. 50%, P = 0.075) and ocular melanocytosis (80% vs. 40%, P = 0.087) appeared to be more frequent in patients with GNA11 mutation compared to those with GNAQ mutations. All four patients diagnosed with cesiomarmorata type or overlapping cesioflammea and cesiomarmorata type PPV carried the GNA11 variant.Interpretation: Our study demonstrated that the majority of PPV patients in the Chinese population carried a postzygotic variant of GNAQ/GNA11, thus further confirming the pathogenic role of GNAQ/GNA11 mosaicism in the development of PPV cesioflammea type.
- Open Access
- 29 July 2023
- Published by Springer Nature in Diagnostic Pathology
- Vol. 18 (1) , 1-6
Desmoplastic small round cell tumor of the liver: diagnosing a rare case on liver biopsy
Desmoplastic small round-cell tumors (DSRCT) frequently develop in the retroperitoneum, pelvis, omentum, and mesentery. Here, we present an unusual case of primary DSRCT in the liver. The patient was an 11-year-old boy with multiple solid masses in the liver parenchyma. The tumor in the needle biopsy had a histology revealing a small round cell morphology and desmoplasia. It shows the immunohistochemical features of DSRCT and documentation of EWSR1-WT1 fusion.A potential diagnostic pitfall is exerted when evaluating liver biopsy, in which DSRCT is a great mimicker and may be easily confused with more common liver malignancies of childhood, such as hepatoblastoma, calcifying nested stromal-epithelial tumor, undifferentiated embryonal sarcoma, and other small round cell tumors, as well as the fibrolamellar variant of hepatocellular carcinoma. This distinction is critical because an accurate therapeutic approach requires a correct diagnosis.
- 29 July 2023
- Published by Springer Nature in Diagnostic Pathology
- Vol. 18 (1) , 1-6
Open AccessDesmoplastic small round cell tumor of the liver: diagnosing a rare case on liver biopsy
Desmoplastic small round-cell tumors (DSRCT) frequently develop in the retroperitoneum, pelvis, omentum, and mesentery. Here, we present an unusual case of primary DSRCT in the liver. The patient was an 11-year-old boy with multiple solid masses in the liver parenchyma. The tumor in the needle biopsy had a histology revealing a small round cell morphology and desmoplasia. It shows the immunohistochemical features of DSRCT and documentation of EWSR1-WT1 fusion.A potential diagnostic pitfall is exerted when evaluating liver biopsy, in which DSRCT is a great mimicker and may be easily confused with more common liver malignancies of childhood, such as hepatoblastoma, calcifying nested stromal-epithelial tumor, undifferentiated embryonal sarcoma, and other small round cell tumors, as well as the fibrolamellar variant of hepatocellular carcinoma. This distinction is critical because an accurate therapeutic approach requires a correct diagnosis.